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Immunotherapy with immunostimulatroy monoclonal
antibodies is based on the ability of antibodies to act as
antagonists of inhibitory receptors or to act as agonists of
costimulatory receptors. Interference of ligand to receptor
binding underlies the first function while crosslinking of
receptors to enforce signaling involves the second mode of
action. Signalling receptors on lymphocytes and antigen
presenting cells are embedded in the plasma membrane
and are functionally linked to adaptors whose function is
conducive to intracelluar signaling events.
In the case of antibodies blocking CTLA-4 functions
multiple mechanism of action take place: (i) efficient
competition for costimulatory interactions of CD28 with
the very same ligands (CD80 and CD86), (ii) functional
expression on the surface of regulatory T cells that can
be depleted by ADCC, (iii) prevention of the denudation
by cooption of CD80 molecules from the surface of anti-
gen presenting cells, a(iv) interference with putative
negative signalling mediated by phosphatases. The
restricted pattern of expression of CTLA-4 on Tregs and
activated T cells is critical to understand its function and
exploitation in immunotherapy.
PD-1 upon interaction with PD-L1 or PD-L2 drives to
the immune synapse the tyrosine phosphatases SHP-1 and
SHP-2. These phosphatases, that are recruited to the cyto-
plasmic tail of PD-1 through its phosphorylated ITIM
motive, dephosphorylate critical tyrosine residues in sig-
naling adaptors activated by the concerted action of the
TCR and CD28. Disruption of signalling in the immune
synapse is prevented by blocking antibodies that avoid the
guidance of PD-1 moieties to the synapse guided by PD-
L1. Avoiding disruption of productive immune synapses is
probably the main mechanism of action of anti-PD-1 and
anti-PD-L1 blocking mAb.
The costimulatory members of the TNFR family trans-
duce costimulatory signals by recruitment of the adptors
TRAF-1, -2, -5. Signal transduction enhances NF-B and
MAPK signaling routes. In this pathway K-63 polyubiqui-
tination reactions are critical for early signaling and are
regulated by specific deubiquitinases. Receptors signal
depending on crosslinking by the agonist antibody. The
pattern of expression of these receptors on the different
subset resting or primed/activated T cells determines
function.
Overall precise understanding of the pattern of distribu-
tions of the receptors on immune cells and the signaling
events that these receptors prevent or elicit will be ulti-
mately important not only to understand the function but
also for both therapeutic manipulation and biomarker
finding.
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